Episodes

  • 42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)

    42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)
    Nov 23 2024

    Discussão do artigo: "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)" de Borchmann P Lancet 2024

    Apresentado por: Dr. Gabriel Coquito

    Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    37 mins
  • 41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

    41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease
    Nov 1 2024

    Discussão do artigo: "An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease" de Kassim A BLOOD 2024

    Apresentado por:Dra. Aline Guerra

    Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    28 mins
  • 40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

    40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
    Sep 27 2024

    Discussão do artigo: "Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission" de Shadman M Blood cancer journal 2024

    Apresentado por: Dra. Camila Frade

    Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    20 mins
  • 39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

    39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
    Sep 25 2024

    Discussão do artigo: "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" de Shaffer B JCO 2024

    Apresentado por: Dra. Marcela Markmann

    Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    31 mins
  • 38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
    Sep 19 2024

    Discussão do artigo: "Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma" de Hungria V NEJM 2024

    Apresentado por: Dr. Matheus Puls

    Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dra. Aline Guerra, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    41 mins
  • 37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

    37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
    Aug 24 2024

    Discussão do artigo: "Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults" de Litzow MR NEJM 2024

    Apresentado por: Dr. Gabriel Coquito

    Discussão por: Dr. Lucas Salviano, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    35 mins
  • 36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

    36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
    Aug 16 2024

    Discussão do artigo: "Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma" de Melani C NEJM 2024

    Apresentado por: Dra. Aline Guerra

    Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    25 mins
  • 35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

    35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
    Aug 5 2024

    Discussão do artigo: "A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia" de Metheny L Blood Adv. 2024 Mar 26;8(6):1384-1391

    Apresentado por: Dra. Thais Araujo

    Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
    Show more Show less
    25 mins